{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-232252","form_type":"8-K","ticker":null,"cik":"0001496323","company_name":"IGM Biosciences, Inc.","filed_at":"2024-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.587059+00:00","generated_at":"2026-05-30T21:25:10.075842+00:00","sec_items":["2.05","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IGM Biosciences pivots to autoimmunity, ends aplitabart work, names new CEO Mary Beth Harler","bullets":["Strategic pivot to focus exclusively on T cell engagers for autoimmune diseases; aplitabart and other oncology programs minimized.","Mary Beth Harler, M.D. appointed CEO and director effective Sept 30, 2024; Fred Schwarzer resigns as CEO and director.","Bruce Keyt, Ph.D. steps down as CSO; Chris Takimoto, M.D., Ph.D. resigns as CMO effective Oct 1, 2024.","Cash runway extended into 2027; reduction in force expected; activities substantially complete by Q1 2025.","Imvotamab (CD20xCD3) ongoing in RA, SLE, myositis; IGM-2644 (CD38xCD3) expected to enter clinic for gMG by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-232252","json":"https://secwatch.observer/filing/0001193125-24-232252.json","markdown":"https://secwatch.observer/filing/0001193125-24-232252.md","text":"https://secwatch.observer/filing/0001193125-24-232252.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496323/000119312524232252/0001193125-24-232252-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496323/000119312524232252/d860501d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:25:10.075842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d1db4e2b3","claim":"Mary Beth Harler, M.D. was appointed as Chief Executive Officer and Director at IGM Biosciences, Inc..","evidence_excerpt":"Mary Beth Harler, M.D. has been appointed as the Company’s Chief Executive Officer, effective as of the Effective Date, and as a member of the Board (initial term ending at the annual stockholder meeting in 2025), effective as of October 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496323/000119312524232252/0001193125-24-232252-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Director"}],"fact_type":"executive_change"},{"claim_id":"a45c5d6b1e","claim":"Fred Schwarzer resigned as Chief Executive Officer, President and Director at IGM Biosciences, Inc..","evidence_excerpt":"In connection with the Strategic Pivot, Fred Schwarzer resigned as Chief Executive Officer, President and a member of the board of directors (the “Board”) of the Company, effective as of September 30, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496323/000119312524232252/0001193125-24-232252-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer, President and Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}